Clinical Trial for Urothelial Cancer and Urinary Bladder Neoplasms.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Urothelial Cancer, Urinary Bladder Neoplasms

Sex

Male or Female

Age

18+ years

Healthy participants

Visit ClinicalTrials.gov for more information

Eligibility criteria

Inclusion criteria

Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion criteria

Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
Prior pelvic radiation for any reason
Inadequate bladder function
Other active malignancies within 3 years prior to randomization
Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
Uncontrolled diabetes
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
Active keratitis or corneal ulcerations
History of autoimmune disease that has required systemic treatment in the past 2 years
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
Prior allogeneic stem cell or solid organ transplant
Received a live attenuated vaccine within 30 days prior to randomization

Study overview

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

View locations for this study

Find the closest location, your results will be shown below

Find the closest location

Miles

0500

Nearest Locations found

9 sites found

Compass Oncology - West

Tigard, Oregon, United States, 97223

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Illinois Cancer Specialists

Niles, Illinois, United States, 60714

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Medical Oncology Hematology Consultants

Newark, Delaware, United States, 19713

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Samsun Clinic - Ridley-Tree Cancer Center

Santa Barbara, California, United States, 93105

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Texas Oncology

Austin, Texas, United States, 78705

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Texas Oncology - Northeast Texas

Tyler, Texas, United States, 75702

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Virginia Oncology Associates

Norfolk, Virginia, United States, 23502

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Williamette Valley Cancer Institute and Research Center

Eugene, Oregon, United States, 97401

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Recruitment Status
Site details
Study Contact
Clinical Trials ID

Join PfizerConnect

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Join PfizerConnect

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?